Skip to content

Natalizumab

Tysabri (natalizumab) is an antibody pharmaceutical. Natalizumab was first approved as Tysabri on 2004-11-23. It is used to treat crohn disease and multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against integrin alpha-4.
Trade Name Tysabri
Common Name Natalizumab
Indication crohn disease, multiple sclerosis
Drug Class Monoclonal antibodies: humanized, immunomodulating
Natalizumab
Get full access now